First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
Status:
Completed
Trial end date:
2016-10-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI
and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type
psoriasis.